## Inari Medical (NARI) Earnings Preview: What to Expect on October 28th
Investors are gearing up for Inari Medical’s (NARI) quarterly earnings report, scheduled for release on Monday, October 28th, 2024. While analysts predict an earnings per share (EPS) of $-0.11, the real focus will be on the company’s guidance and any indications of positive growth for the future. Let’s delve into the key factors investors should consider ahead of the announcement.
A Look Back: Inari Medical’s Earnings Track Record
Inari Medical’s recent earnings history has been a rollercoaster ride for shareholders. Last quarter, the company missed EPS estimates by a significant $0.35, resulting in a 10.65% drop in share price the following day. This highlights the importance of not just beating estimates, but also providing optimistic guidance for the next quarter.
Here’s a closer look at Inari Medical’s earnings performance over the past year and the subsequent price changes:
| Quarter | EPS Estimate | EPS Actual | Price Change % |
|—|—|—|—|
| Q2 2024 | -0.13 | -0.48 | -11.0% |
| Q1 2024 | -0.20 | -0.33 | 11.0% |
| Q4 2023 | 0.01 | -0.08 | -21.0% |
| Q3 2023 | 0 | 0.05 | -17.0% |
Current Market Sentiment and Analyst Expectations
Staying informed about market sentiment and industry expectations is crucial for investors. Currently, Inari Medical has received a total of 9 ratings from analysts, with a consensus rating of Neutral. The average one-year price target sits at $57.22, suggesting a potential 30.16% upside.
Peer Comparisons: Gauging Inari Medical’s Relative Standing
To get a better understanding of Inari Medical’s performance, it’s helpful to compare it to its peers in the medical device industry. We’ll look at QuidelOrtho, iRhythm Technologies, and Enovis, three prominent players in the space:
| Company | Consensus Rating | Average 1-Year Price Target | Potential Upside |
|—|—|—|—|
| QuidelOrtho | Outperform | $57.25 | 30.23% |
| iRhythm Technologies | Buy | $109.1 | 148.18% |
| Enovis | Outperform | $58.75 | 33.64% |
Snapshot: Key Metrics for Inari Medical and its Peers
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|—|—|—|—|—|
| Inari Medical | Neutral | 22.53% | $125.83M | -7.20% |
| QuidelOrtho | Outperform | -4.22% | $276M | -4.56% |
| iRhythm Technologies | Buy | 19.27% | $103.47M | -21.22% |
| Enovis | Outperform | 22.56% | $288.88M | -0.57% |
Key Takeaway: Inari Medical leads its peers in revenue growth and gross profit, but lags behind in return on equity. This suggests the company may need to improve its profitability and shareholder value.
Inari Medical: A Deeper Dive
Inari Medical Inc is a medical device company dedicated to developing innovative solutions for patients suffering from Chronic Venous Disease. Its product portfolio includes:
*
ClotTriever:
A device used for removing clots from peripheral blood vessels, often used to treat deep vein thrombosis.*
FlowTriever System:
Designed for the treatment of pulmonary embolism.*
InThrill System:
Used for the treatment of small vessel thrombosis.*
LimFlow System:
And other products focused on addressing various aspects of venous disease.Inari Medical derives a majority of its revenue from the United States, with a growing presence in international markets.
Financial Highlights: Examining Inari Medical’s Key Metrics
*
Market Capitalization:
Inari Medical’s market capitalization currently falls below industry benchmarks, indicating a smaller size compared to its peers. This may be due to various factors such as growth expectations or operational capacity.*
Revenue Growth:
Over the past three months (as of June 30, 2024), Inari Medical achieved a solid revenue growth rate of approximately 22.53%. This demonstrates a notable increase in the company’s top-line earnings. However, compared to other companies in the Healthcare sector, the company’s growth rate is lower than the average.*
Net Margin:
Inari Medical’s net margin is below industry standards, highlighting challenges in achieving strong profitability. A net margin of -21.5% suggests potential difficulties in effective cost control.*
Return on Equity (ROE):
Inari Medical’s ROE surpasses industry benchmarks, reaching -7.2%. This indicates robust financial management and efficient utilization of shareholder equity capital.*
Return on Assets (ROA):
Inari Medical’s ROA lags behind industry averages, implying challenges in maximizing returns from its assets. An ROA of -4.7% indicates potential hurdles in achieving optimal financial performance.*
Debt Management:
Inari Medical’s debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity. This can be viewed positively by investors.Stay Informed: Track Inari Medical’s Earnings Releases
To stay updated on all earnings releases for Inari Medical, visit the earnings calendar on our site. This will provide you with the latest information and analysis to help you make informed investment decisions.
